Search
Luteci (177Lu) oxodotreotida per al tractament de tumors neuroendocrins gastroenteropancreàtics positius al receptor de somatostatina, ben diferenciats, progressius i irresecables o metastàtics
(2020-07-07)
Neuroendocrine tumors (TNEs) are defined as those neoplasms with a predominantly neuroendocrine cell differentiation, which can arise in most organs, although most are of gastrointestinal or pancreatic origin (≈65%). The ...
Àcid obeticòlic en combinació amb àcid ursodesoxicòlic (AUDC) per al tractament de la colangitis biliar primària que no respon adequadament a l’AUDC o en monoteràpia en adults que no toleren l’AUDC: informe d’avaluació de resultats
(2020-12)
Primary biliary cholangitis (CBP) is a chronic liver disease of autoimmune pathogenesis with a progressive clinical course that evolves over decades. It is characterized by a destruction of the intrahepatic bile ducts with ...
Durvalumab per al tractament del càncer de pulmó no microcític estadi III irresecable
(2020-03-25)
Non-microcytic lung cancer (CPNM) in stage III consists of a heterogeneous population with two subsets: stage IIIA and IIIB. Most patients with stage IIIA / B have an inoperable (non-resectable) disease. Only a third of ...
Upadacitinib per al tractament de l’artritis reumatoide de moderada a greu
(2021-03-03)
Rheumatoid arthritis (RA) is an inflammatory disease of autoimmune etiology characterized by chronic inflammation of the synovial membrane, which leads to the progressive destruction of joint structures. Typical symptoms ...
Sorafenib i lenvatinib per al tractament en primera línia del carcinoma hepatocel·lular (CHC)
(2020-07-29)
Hepatocellular carcinoma (HCC) is the most common primary liver cancer, the fifth most common cancer in men and the seventh in women, and is associated with high mortality, which is the third leading cause of cancer death. ...
Patiròmer i ciclosilicat de sodi i zirconi per al tractament de la hiperpotassèmia
(2021-05-06)
Serum potassium levels (K-S) are normally maintained within narrow limits (3.5-5.0 mmol / L) by multiple mechanisms. Such strict regulation is essential for numerous cellular processes. Imbalances in potassium (K) homeostasis ...
Burosumab per al tractament de la hipofosfatèmia congènita
(2021-01-21)
X-linked hypophosphatemia (HLX) is a dominant, chronic, and debilitating inherited disease caused by inactivating mutations in the PHEX gene (Phosphate-regulating gene with homologies to endopeptidases on the X chromosome). ...
Pertuzumab en combinació amb trastuzumab i quimioteràpia per al tractament neoadjuvant de pacients adults amb càncer de mama HER2 positiu, localment avançat, inflamatori, o en estadi precoç amb alt risc de recaiguda: informe d'avaluació de resultats
(2020)
Breast cancer (BC) is the most common neoplasm in women and the leading cause of cancer death in European women. Pertuzumab is a monoclonal antibody that inhibits epidermal growth factor (HER2) receptor 2 dimerization. The ...